The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance A021302) Impac.
 
Manish A. Shah
Consulting or Advisory Role - Lilly
Research Funding - Gilead Sciences (Inst); Lilly/ImClone (Inst); Merck (Inst); Sanofi/Regeneron (Inst)
 
Qian Shi
No Relationships to Disclose
 
Vivian E. Strong
No Relationships to Disclose
 
Jon Strasser
Speakers' Bureau - Genomic Health; Insys Therapeutics
 
David H. Ilson
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Genentech/Roche
 
Lawrence Kleinberg
No Relationships to Disclose
 
Syma Iqbal
No Relationships to Disclose
 
Evan John Wuthrick
No Relationships to Disclose
 
Alexandra Levasseur
No Relationships to Disclose
 
Nathan Hall
No Relationships to Disclose
 
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)